

Contact: Jessica Corkran, Executive Director ECD Global Alliance (337) 502-8034 jessica.corkran@erdheim-chester.org

FOR IMMEDIATE RELEASE


California Care Center Added to Rare Disease Global Network

Stanford Health Care is the second California health system to join the Erdheim-Chester Disease Care Center Network.

DeRidder, LA – June 26, 2018 – The Erdheim-Chester Disease Global Alliance (ECDGA) welcomes the Stanford Histiocytosis Program at Stanford Health Care as the newest ECD Emerging Care Center. Stanford joins with Seattle Cancer Care Alliance and University of California, San Diego to serve patients in the western US.

Beth A. Martin, MD, an adult hematologist-oncologist, will lead the Stanford care center team of specialists who are interested in treating ECD patients with the most up-to-date care available. The complex presentation of ECD often requires many types of specialists to diagnose and treat this rare cancer; therefore, each center has a dedicated team ready.

Since 2015, the ECD Care Center network has grown to 32 locations worldwide, which directly serve more than 300 ECD patients. Available treatment options for patients living with ECD can be accessed and prescribed at all ECD Care Centers. Additionally, the centers ensure that patients are provided a treatment plan within eight weeks of their first evaluation.



Patients seen at an ECD Care Center are empowered by the knowledge that an experienced team of doctors and researchers are consistently collaborating and are determined to improve ECD care every day.

The ECD Referral Care Center Network provides ECD patients simpler way to find ECD-knowledgeable doctors who have the time and expertise to help patients. The lead physicians at these centers will accept new ECD patients and provide consultation on ECD cases at other centers.

To learn more about the ECD Care Center network and how to contact them, visit <u>http://erdheim-chester.org/care-centers/</u>. To nominate an institution for the network, please <u>contact us</u>.

Erdheim-Chester Disease is an ultra-rare condition that is believed to be under diagnosed. It is considered a histiocytic neoplasm (type of blood cancer). The illness is characterized by the accumulation of histiocytes, cells that normally fight infections, in tissue and organs. The tissue and organs become dense and fibrotic due to the infiltration of the histiocytes and can lead to organ failure unless a successful treatment is found.

The ECD Global Alliance is a 501(c)(3) non-profit organization dedicated to awareness, support, education, and research related to Erdheim-Chester Disease.